Journal: EMBO Molecular Medicine

Article Title: Targeting cIAP2 in a novel senolytic strategy prevents glioblastoma recurrence after radiotherapy

doi: 10.1038/s44321-025-00201-x

Figure Lengend Snippet: Reagents and tools table

Article Snippet: c-IAP2 siRNA (h) , Santa Cruz Biotechnology, Inc , sc-29850.

Techniques: Biomarker Discovery, Purification, Sequencing, Negative Control, Plasmid Preparation, Fluorsave, SYBR Green Assay, Western Blot, Stripping, Software

Journal: EMBO Molecular Medicine

Article Title: Targeting cIAP2 in a novel senolytic strategy prevents glioblastoma recurrence after radiotherapy

doi: 10.1038/s44321-025-00201-x

Figure Lengend Snippet: Reagents and tools table

Article Snippet: Anti-c-IAP2 (58C7) Rabbit mAb , Cell Signaling Technology , 3130.

Techniques: Biomarker Discovery, Purification, Sequencing, Negative Control, Plasmid Preparation, Fluorsave, SYBR Green Assay, Western Blot, Stripping, Software

Journal: Scientific Reports

Article Title: Inhibition of AKT enhances chemotherapy efficacy and synergistically interacts with targeting of the Inhibitor of apoptosis proteins in oesophageal adenocarcinoma

doi: 10.1038/s41598-024-83912-4

Figure Lengend Snippet: Characterisation of IAP proteins in OAC cells. ( A ) Western blot analysis of cleaved PARP, cIAP1, cIAP2, XIAP and Survivin following 24 h treatment with ~ IC 30(72 h) doses of chemotherapy in OE33, FLO1 and OE19 cell lines. Western blot analysis of basal IAP protein levels in ( B ) paired sensitive and resistant OAC cell lines and ( C ) an OAC cell line panel. Vinculin was used as a loading control ( D ) Pearson correlation analysis of wild-type XIAP protein levels and ALM301 sensitivity, ~ IC50 (72 h) in the OAC cell line panel (r = 0.79, p < 0.05). XIAP mutant KYAE1 cell line was omitted from the analysis due to predicted functionality effect.

Article Snippet: Western blot analysis was carried out as previously described using antibodies targeting phospho-(S473)-Akt (Cell Signaling Technology Cat# 4060, RRID:AB_2315049), phospho-(T308)-Akt (Cell Signaling Technology Cat# 4056, RRID:AB_331163), pan- Akt (Cell Signaling Technology Cat# 2920, RRID:AB_1147620), PTEN (Cell Signaling Technology Cat# 9559, RRID:AB_390810), PARP (Cell Signaling Technology Cat# 9532, RRID:AB_659884), phospho-γ-H2AX (Cell Signaling Technology Cat# 9718, RRID:AB_2118009), cIAP1 (Cell Signaling Technology Cat# 7065, RRID:AB_10890862), cIAP2 (Cell Signaling Technology Cat# 3130, RRID:AB_10693298), XIAP (Cell Signaling Technology Cat# 2045, RRID:AB_2214866) and Survivin (Cell Signaling Technology Cat# 2808, RRID:AB_2063948).

Techniques: Western Blot, Control, Mutagenesis

Journal: Scientific Reports

Article Title: Inhibition of AKT enhances chemotherapy efficacy and synergistically interacts with targeting of the Inhibitor of apoptosis proteins in oesophageal adenocarcinoma

doi: 10.1038/s41598-024-83912-4

Figure Lengend Snippet: IAP antagonist activity in OAC cells ( A ) Western blot analysis of cleaved PARP, cIAP1, cIAP2, XIAP and Survivin protein levels following 24 h treatment with SMC, BV6. Vinculin was used as a loading control. ( B ) MTT analysis of OAC cell viability following 72 h treatment with BV6.

Article Snippet: Western blot analysis was carried out as previously described using antibodies targeting phospho-(S473)-Akt (Cell Signaling Technology Cat# 4060, RRID:AB_2315049), phospho-(T308)-Akt (Cell Signaling Technology Cat# 4056, RRID:AB_331163), pan- Akt (Cell Signaling Technology Cat# 2920, RRID:AB_1147620), PTEN (Cell Signaling Technology Cat# 9559, RRID:AB_390810), PARP (Cell Signaling Technology Cat# 9532, RRID:AB_659884), phospho-γ-H2AX (Cell Signaling Technology Cat# 9718, RRID:AB_2118009), cIAP1 (Cell Signaling Technology Cat# 7065, RRID:AB_10890862), cIAP2 (Cell Signaling Technology Cat# 3130, RRID:AB_10693298), XIAP (Cell Signaling Technology Cat# 2045, RRID:AB_2214866) and Survivin (Cell Signaling Technology Cat# 2808, RRID:AB_2063948).

Techniques: Activity Assay, Western Blot, Control

Journal: Cell Reports Medicine

Article Title: Castrate-resistant prostate cancer response to taxane is determined by an HNF1-dependent apoptosis resistance circuit

doi: 10.1016/j.xcrm.2024.101868

Figure Lengend Snippet:

Article Snippet: c-IAP2 (58C7) Antibody , Cell Signaling , 3130; RRID: AB_10693298.

Techniques: Recombinant, Electron Microscopy, Plasmid Preparation, Software